The 4G/5G-polymorphism in the PAI-1 gene is not associated with markers of atherosclerosis in male smokers

Thrombosis Research

Volumn 107, Issue 3-4, 2002, Pages 115-119

  Hoekstra, Tiny ^a   Geleijnse, Johanna M ^a   De Waart, Frouwkje ^a   Nederhand, Rene ^b   Kluft, Cornelis ^b   Kok, Frans J ^a   Schouten, Evert G ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

Author keywords

4G 5G polymorphism; Ankle brachial index; Atherosclerosis; Intima media thickness; Plasminogen activator inhibitor type 1

Indexed keywords

ADULT; AGED; ANKLE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ISOLATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INTIMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; ARTERIOSCLEROSIS; BLOOD PRESSURE; BRACHIAL ARTERY; CAROTID ARTERY; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; VASCULARIZATION;

BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1;

AGED; ANKLE; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; CAROTID ARTERIES; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; SMOKING; TUNICA INTIMA;

EID: 0037104680     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00254-2     Document Type: Article

References (28)

1. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur. Heart J. 19(Suppl. C):1998;C39-C43.
2. Kohler H.P., Grant P.J. Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342:2000;1792-1801.
3. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268:1993;10739-10745.
4. Eriksson P., Kallin B., van't Hooft F., Båvenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1851-1855.
5. Burzotta F., Di Castelnuovo A., Amore C., D'Orazio A., Di Bitondo R., Donati M.B.et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb. Haemost. 79:1998;354-358.
6. Margaglione M., Cappucci G., d'Addedda M., Colaizzo D., Giuliani N., Vecchione G.et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis - Relation to environmental and genetic determinants. Arterioscler. Thromb. Vasc. Biol. 18:1998;562-567.
7. Henry M., Chomiki N., Scarabin P.Y., Alessi M.C., Peiretti F., Arveiler D.et al. Five frequent polymorphisms of the PAI-1 gene - Lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler. Thromb. Vasc. Biol. 17:1997;851-858.
8. Cesari M., Sartori M.T., Patrassi G.M., Vettore S., Rossi G.P. Determinants of plasma levels of plasminogen activator inhibitor-1-A study of normotensive twins. Arterioscler. Thromb. Vasc. Biol. 19:1999;316-320.
9. Boekholdt S.M., Bijsterveld N.R., Moons A.H.M., Levi M., Büller H.R., Peters R.J.G. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulation. 104:2001;3063-3068.
10. Iacoviello L., Burzotta F., Di Castelnuova A., Zito F., Marchioli R., Donati M.B. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb. Haemost. 80:1998;1029-1030.
11. Gardemann A., Lohre J., Katz N., Tillmanns H., Hehrlein F.W., Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb. Haemost. 82:1999;1121-1126.
12. Folsom A.R., Pankow J.S., Williams R.R., Evans G.W., Province M.A., Eckfeldt J.H. Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb. Haemost. 79:1998;400-404.
13. Salomaa V., Stinson V., Kark J.D., Folsom A.R., Davis C.E., Wu K.K. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Circulation. 91:1995;284-290.
14. Grancha S., Estelles A., Falco C., Chirivella N., Espana F., Aznar J. Detailed localization of type-1 plasminogen activator inhibitor mRNA expression and antigen in atherosclerotic plaque on human coronary artery. Fibrinolysis Proteolysis. 12:1998;53-60.
15. Stoop A.A., Lupu F., Pannekoek H. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall-A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler. Thromb. Vasc. Biol. 20:2000;1143-1149.
16. Salame M.Y., Samani N.J., Masood I., deBono D.P. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis. 152:2000;19-28.
17. De Waart F.G., Smilde T., Wollersheim H., Stalenhoef A.F.H., Kok F.J. Smoking characteristics, antioxidant vitamins, and carotid artery wall thickness among life-long smokers. J. Clin. Epidemiol. 53:2000;707-714.
18. Smilde T.J., Wollersheim H., Van Langen H., Stalenhoef A.F.H. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima media thickness. Clin. Sci. 93:1997;317-324.
19. Feyerabend C., Bryant A.E., Jarvis M.J., Russell M.A. Determination of cotinine in biological fluids of non-smokers by packed column gas-liquid chromatography. J. Pharm. Pharmacol. 38:1986;917-919.
20. Demacker P.N., Hijmans A.G., Vos J.H., van't Laar A., Jansen A.P. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin. Chem. 26:1980;1775-1779.
21. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
22. Mansfield M.W., Stickland M.H., Grant P.J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb. Haemost. 74:1995;842-847.
23. Margaglione M., Grandone E., Cappucci G., Colaizzo D., Giuliani N., Vecchione G.et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb. Haemost. 77:1997;605-606.
24. Ossei-Gerning N., Mansfield M.W., Stickland M.H., Wilson I.J., Grant P.J. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler. Thromb. Vasc. Biol. 17:1997;33-37.
25. Achimastos A., Brahimi M., Raison J., Billaud E., Ayache M., Moatti N.et al. Plasma insulin, plasminogen activator inhibitor, and ankle-brachial systolic blood pressure ratio in overweight hypertensive subjects. J. Hum. Hypertens. 13:1999;329-335.
26. Van der Bom J., Bots M.L., Haverkate F., Meyer P., Hofman A., Grobbee D.E.et al. Fibrinolytic activity in peripheral atherosclerosis in the elderly. Thromb. Haemost. 81:1999;275-280.
27. Feinstein S.B., Voci P., Pizzuto F. Noninvasive surrogate markers of atherosclerosis. Am. J. Cardiol. 89:2002;31C-44C.
28. Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation. 99:1999;2496-2498.